S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:CDXC

ChromaDex (CDXC) Stock Forecast, Price & News

$1.59
+0.02 (+1.27%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.57
$1.61
50-Day Range
$1.31
$1.59
52-Week Range
$1.15
$2.37
Volume
68,732 shs
Average Volume
149,893 shs
Market Capitalization
$119.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.57

ChromaDex MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
187.2% Upside
$4.57 Price Target
Short Interest
Bearish
3.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.01mentions of ChromaDex in the last 14 days
Based on 11 Articles This Week
Insider Trading
Acquiring Shares
$20,160 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.14) to ($0.06) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

313th out of 986 stocks

Medicinals & Botanicals Industry

2nd out of 11 stocks


CDXC stock logo

About ChromaDex (NASDAQ:CDXC) Stock

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Stock News Headlines

Master Market Movements: Free Stock Analysis Report with Predictive Buy/Sell/Hold Insights!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
H.C. Wainwright Keeps Their Buy Rating on Chromadex (CDXC)
StockNews.com Downgrades ChromaDex (NASDAQ:CDXC) to Buy
Master the Market: Free Stock Analysis + Buy/Sell/Hold Signals!
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Recap: ChromaDex Q1 Earnings
ChromaDex (CDXC) Scheduled to Post Earnings on Wednesday
ChromaDex Co. (NASDAQ:CDXC) Short Interest Down 6.7% in March
See More Headlines

CDXC Price History

CDXC Company Calendar

Last Earnings
3/08/2023
Today
6/09/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDXC
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.57
High Stock Price Forecast
$6.60
Low Stock Price Forecast
$2.10
Forecasted Upside/Downside
+184.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-16,540,000.00
Pretax Margin
-13.84%

Debt

Sales & Book Value

Annual Sales
$72.05 million
Book Value
$0.39 per share

Miscellaneous

Free Float
67,042,000
Market Cap
$120.33 million
Optionable
Optionable
Beta
1.79

Key Executives

  • Robert N. FriedRobert N. Fried
    Chief Executive Officer & Director
  • Brianna Gerber
    Chief Financial Officer
  • Fadi Karam
    Chief Marketing Officer
  • Trent Crane
    Regional Vice President-Sales
  • Heather Van Blarcom
    Secretary & Senior Vice President-Legal













CDXC Stock - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CDXC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CDXC, but not buy additional shares or sell existing shares.
View CDXC analyst ratings
or view top-rated stocks.

What is ChromaDex's stock price forecast for 2023?

3 brokers have issued 1 year price objectives for ChromaDex's shares. Their CDXC share price forecasts range from $2.10 to $6.60. On average, they predict the company's stock price to reach $4.57 in the next twelve months. This suggests a possible upside of 184.5% from the stock's current price.
View analysts price targets for CDXC
or view top-rated stocks among Wall Street analysts.

How have CDXC shares performed in 2023?

ChromaDex's stock was trading at $1.68 at the beginning of the year. Since then, CDXC shares have decreased by 4.5% and is now trading at $1.6050.
View the best growth stocks for 2023 here
.

When is ChromaDex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our CDXC earnings forecast
.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) issued its quarterly earnings data on Wednesday, March, 8th. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. The company earned $21 million during the quarter, compared to analysts' expectations of $21.08 million. ChromaDex had a negative trailing twelve-month return on equity of 51.99% and a negative net margin of 13.84%. During the same quarter in the prior year, the firm earned ($0.08) EPS.

What guidance has ChromaDex issued on next quarter's earnings?

ChromaDex issued an update on its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.06M-, compared to the consensus revenue estimate of $82.65 million.

What is Robert Fried's approval rating as ChromaDex's CEO?

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?
What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Tieton Capital Management LLC (3.41%), BlackRock Inc. (1.20%), Renaissance Technologies LLC (0.57%), GMT Capital Corp (0.40%), Cambridge Investment Research Advisors Inc. (0.26%) and State Street Corp (0.25%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried, Stephen A Block and Steven D Rubin.
View institutional ownership trends
.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $1.61.

How much money does ChromaDex make?

ChromaDex (NASDAQ:CDXC) has a market capitalization of $120.33 million and generates $72.05 million in revenue each year. The company earns $-16,540,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does ChromaDex have?

The company employs 115 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294.

This page (NASDAQ:CDXC) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -